Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: A cost-effectiveness analysis

Value in Health

Volumn 16, Issue 8, 2013, Pages 1123-1132

  Johal, Sukhvinder ^a   Ralston, Stephen ^b   Knight, Christopher ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b Takeda Global Research and Development Centre (Europe) Ltd   (United Kingdom)

Author keywords

cost effectiveness analysis; discount rate; NICE appraisal; osteosarcoma; ultra orphan

Indexed keywords

AGALSIDASE BETA; ALGLUCERASE; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; ILOPROST; LARONIDASE; METHOTREXATE; MIFAMURTIDE; MIGLUSTAT; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ADOLESCENT; ARTICLE; CANCER RECURRENCE; CHILL; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; FEVER; FLU LIKE SYNDROME; HEALTH CARE COST; HEARING IMPAIRMENT; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH SERVICE; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME;

COST-EFFECTIVENESS ANALYSIS; DISCOUNT RATE; NICE APPRAISAL; OSTEOSARCOMA; ULTRA-ORPHAN;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; COST-BENEFIT ANALYSIS; HUMANS; MARKOV CHAINS; OSTEOSARCOMA; PHOSPHATIDYLETHANOLAMINES; QUALITY-ADJUSTED LIFE YEARS;

EID: 84890316417     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.08.2294     Document Type: Article

References (40)

1. D. Carrle, and S.S. Bielack Current strategies of chemotherapy in osteosarcoma Int Orthop 30 2006 445 451
2. C.A. Stiller, E. Desandes, and S.E. Danon Cancer incidence and survival in European adolescents (1978-1997): report from the Automated Childhood Cancer Information System project Eur J Cancer 42 13 2006 2006 2018
3. C. Stiller, M. Quinn, and S. Rowan Childhood Cancer: The Health of Children and Young People 2004 Office for National Statistics London
4. A. Longhi, C. Errani, and M. De Paolis Primary bone osteosarcoma in the pediatric age: state of the art Cancer Treat Rev 32 6 2006 423 436
5. W.S. Ferguson, and A.M. Goorin Current treatment of osteosarcoma Cancer Invest 19 3 2001 292 315
6. S.C. Kaste, C.B. Pratt, and A.M. Cain Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features Cancer 86 8 1999 1602 1608
7. National Institute for Health and Care Excellence. NICE Citizens Council report: ultra orphan drugs. 2004. Available at: http://www.nice.org.uk/ niceMedia/pdf/Citizens-Council-Ultraorphan.pdf. [Accessed May 1, 2012].
8. L. Kager, U. Potschger, and S. Bielack Review of mifamurtide in the treatment of patients with osteosarcoma Ther Clin Risk Manag 6 2010 279 286
9. G.J. Myers, A.T. Abudu, and S.R. Carter Endoprosthetic replacement of the distal femur for bone tumours: long-term results J Bone Joint Surg Br 89 2007 521 526
10. P.C. Hogendoorn, N. Athanasou, and S. Bielack Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v204 v213
11. N. Fuchs, S.S. Bielack, and D. Epler Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs Ann Oncol 9 1998 893 899
12. M. Eselgrim, H. Grunert, and T. Kuhne Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials Pediatr Blood Cancer 47 2006 42 50
13. P.A. Meyers, C.L. Schwartz, and M. Krailo Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate J Clin Oncol 23 2005 2004 2011
14. P.A. Meyers, C.L. Schwartz, and M.D. Krailo Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group J Clin Oncol 26 2008 633 638
15. National Institute for Health and Care Excellence. Technology appraisal guidance 235: mifamurtide for the treatment of osteosarcoma. 2011. Available at: http://www.nice.org.uk/nicemedia/live/13593/56821/56821.pdf. [Accessed May 1, 2012].
16. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2008. Available at: http://www.nice.org.uk/media/B52/ A7/TAMethodsGuideUpdatedJune2008.pdf. [Accessed May 1, 2012].
17. S. Ferrari, A. Briccoli, and M. Mercuri Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival J Clin Oncol 21 2003 710 715
18. C.W. Karlson, and M.A. Rapoff Attrition in randomized controlled trials for pediatric chronic conditions J Pediatr Psychol 34 2009 782 793
19. Pandor A, FitzGerald P, Stevenson M, et al. Mifamurtide for osteosarcoma. 2009. Available at: http://www.hta.nhs.uk/erg/reports/1772.pdf. [Accessed May 1, 2012].
20. Joint Formulary Committee British National Formulary 56 Edition 2008 BMJ Group and Pharmaceutical Press London
21. National Health Service. Department of Health reference costs 2007-08. 2008. Available at: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/ en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH-098945. [Accessed May 1, 2012].
22. The European and American Osteosarcoma Study Group. EURAMOS 1 Study Protocol. 2001. Available at: http://www.ctu.mrc.ac.uk/euramos/euramos-i-trial. asp. [Accessed May 1, 2012].
23. R.J. Grimer, S.R. Carter, and P.B. Pynsent The cost-effectiveness of limb salvage for bone tumours J Bone Joint Surg Br 79 1997 558 561
24. Office for National Statistics. Consumer price indices. Available at: http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Consumer+Price+Indices. [Accessed May 1, 2012].
25. J.F. Guest, F.J. Ruiz, and M.J. Greener Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK Eur J Cancer Care (Engl) 15 2006 65 73
26. J. Lundkvist, M. Ekman, and S.R. Ericsson Proton therapy of cancer: potential clinical advantages and cost-effectiveness Acta Oncol 44 2005 850 861
27. D. Alessi, E. Dama, and R. Barr Health-related quality of life of long-term childhood cancer survivors: a population-based study from the Childhood Cancer Registry of Piedmont, Italy Eur J Cancer 43 2007 2545 2552
28. A.H. Briggs, A.E. Ades, and M.J. Price Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework Med Decis Making 23 2003 341 350
29. A. Briggs, M. Sculpher, and K. Claxton Decision Modelling for Health Economic Evaluation 2006 Oxford University Press Oxford, UK
30. National Institute for Health and Care Excellence. Appraising orphan drugs (DRAFT). 2006. Available at: http://www.nice.org.uk/niceMedia/pdf/smt/ 120705item4.pdf. [Accessed May 1, 2012].
31. J.L. Severens, and R.J. Milne Discounting health outcomes in economic evaluation: the ongoing debate Value Health 7 2004 397 401
32. A.L. Hillman, and M.S. Kim Economic decision making in healthcare: a standard approach to discounting health outcomes Pharmacoeconomics 7 1995 198 205
33. M. Krahn, and A. Gafni Discounting in the economic evaluation of health care interventions Med Care 31 1993 403 418
34. Sussex J, Shah K. The publicly funded vaccines market in the UK. Office of Health Economics Consulting Report 10/01. 2010. Available at: http://www.ohe.org/publications/article/the-publicly-funded-vaccines-market-in- the-uk-19.cfm. [Accessed May 1, 2012].
35. M.F. Drummond, D.A. Wilson, and P. Kanavos Assessing the economic challenges posed by orphan drugs Int J Technol Assess Health Care 23 2007 36 42
36. M. Schlander The use of cost-effectiveness by the National Institute for Health and Care Excellence (NICE): no(t yet an) exemplar of a deliberative process J Med Ethics 34 2008 534 539
37. D.A. Hughes, B. Tunnage, and S.T. Yeo Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM 98 2005 829 836
38. M. Drummond, B. Evans, and J. LeLorier Evidence and values: requirements for public reimbursement of drugs for rare diseases - a case study in oncology Can J Clin Pharmacol 16 2 2009 e273 e281 discussion e82-4
39. J. Brazier, J. Ratcliffe, and A. Tsuchiya Measuring and Valuing Health Benefits for Economic Evaluation 2007 Oxford University Press Oxford, UK
40. C. McCabe, K. Claxton, and A. Tsuchiya Orphan drugs and the NHS: should we value rarity? BMJ 331 2005 1016 1019